Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317862924> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W4317862924 endingPage "TPS766" @default.
- W4317862924 startingPage "TPS766" @default.
- W4317862924 abstract "TPS766 Background: While treatment of pancreatic cancer has advanced, survival rates remain low. Stereotactic body radiotherapy (SBRT; high dose per fraction radiation) may exhibit improved clinical outcomes in locally advanced pancreatic cancer but carries potential gastrointestinal toxicity risks. Rucosopasem (GC4711) is one of a class of investigational selective dismutase mimetics that rapidly and specifically converts superoxide to hydrogen peroxide. Studies have shown that normal cells tolerate hydrogen peroxide fluxes better than cancer cells. As radiation response modifiers, dismutase mimetics have the potential to increase tumor control of SBRT without compromising radiation safety. In a pilot phase 1/2 trial in patients with pancreatic cancer, avasopasem, a dismutase mimetic related to rucosopasem, nearly doubled median overall survival in patients receiving SBRT vs placebo plus SBRT. Improvements versus placebo were also observed in local tumor control, time to metastases, and progression-free survival. Altogether, these data support the hypothesis that rucosopasem may improve survival and the benefit-risk ratio of SBRT by improving efficacy without increasing gastrointestinal toxicity. Methods: GRECO-2 is a phase 2, multicenter, randomized, double-blind, placebo-controlled study (NCT04698915) to determine the effect of adding rucosopasem to SBRT on overall survival in patients with borderline resectable or locally advanced, unresectable nonmetastatic pancreatic cancer following initial chemotherapy with a FOLFIRINOX-based regimen or a gemcitabine doublet. Approximately 160 patients will be randomized (approximately 35 sites) to receive rucosopasem 100 mg or placebo via IV infusion over 15 minutes, prior to each SBRT fraction (5 x 10 Gy). Patients judged to be resectable will undergo surgical exploration within 8 weeks after SBRT. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, locoregional control, time to metastasis, surgical resection rate, RO resection rate, best overall response, in-field local response, and safety (acute and late toxicities). Exploratory endpoints include PRO-CTCAE and CA19-9 normalization. This trial (NCT04698915) is now enrolling. Clinical trial information: NCT04698915 ." @default.
- W4317862924 created "2023-01-25" @default.
- W4317862924 creator A5006838528 @default.
- W4317862924 creator A5014809735 @default.
- W4317862924 creator A5021903894 @default.
- W4317862924 creator A5029742035 @default.
- W4317862924 creator A5031878697 @default.
- W4317862924 creator A5035589941 @default.
- W4317862924 creator A5036054930 @default.
- W4317862924 creator A5037353312 @default.
- W4317862924 creator A5048486702 @default.
- W4317862924 creator A5056260462 @default.
- W4317862924 creator A5068276723 @default.
- W4317862924 creator A5071977925 @default.
- W4317862924 creator A5075592761 @default.
- W4317862924 creator A5089299130 @default.
- W4317862924 date "2023-02-01" @default.
- W4317862924 modified "2023-10-13" @default.
- W4317862924 title "Greco-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with rucosopasem (GC4711) in the treatment of locally advanced or borderline resectable nonmetastatic pancreatic cancer." @default.
- W4317862924 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.tps766" @default.
- W4317862924 hasPublicationYear "2023" @default.
- W4317862924 type Work @default.
- W4317862924 citedByCount "1" @default.
- W4317862924 countsByYear W43178629242023 @default.
- W4317862924 crossrefType "journal-article" @default.
- W4317862924 hasAuthorship W4317862924A5006838528 @default.
- W4317862924 hasAuthorship W4317862924A5014809735 @default.
- W4317862924 hasAuthorship W4317862924A5021903894 @default.
- W4317862924 hasAuthorship W4317862924A5029742035 @default.
- W4317862924 hasAuthorship W4317862924A5031878697 @default.
- W4317862924 hasAuthorship W4317862924A5035589941 @default.
- W4317862924 hasAuthorship W4317862924A5036054930 @default.
- W4317862924 hasAuthorship W4317862924A5037353312 @default.
- W4317862924 hasAuthorship W4317862924A5048486702 @default.
- W4317862924 hasAuthorship W4317862924A5056260462 @default.
- W4317862924 hasAuthorship W4317862924A5068276723 @default.
- W4317862924 hasAuthorship W4317862924A5071977925 @default.
- W4317862924 hasAuthorship W4317862924A5075592761 @default.
- W4317862924 hasAuthorship W4317862924A5089299130 @default.
- W4317862924 hasConcept C121608353 @default.
- W4317862924 hasConcept C126322002 @default.
- W4317862924 hasConcept C126894567 @default.
- W4317862924 hasConcept C142724271 @default.
- W4317862924 hasConcept C143998085 @default.
- W4317862924 hasConcept C204787440 @default.
- W4317862924 hasConcept C27081682 @default.
- W4317862924 hasConcept C2780210213 @default.
- W4317862924 hasConcept C2780258809 @default.
- W4317862924 hasConcept C2781413609 @default.
- W4317862924 hasConcept C509974204 @default.
- W4317862924 hasConcept C71924100 @default.
- W4317862924 hasConceptScore W4317862924C121608353 @default.
- W4317862924 hasConceptScore W4317862924C126322002 @default.
- W4317862924 hasConceptScore W4317862924C126894567 @default.
- W4317862924 hasConceptScore W4317862924C142724271 @default.
- W4317862924 hasConceptScore W4317862924C143998085 @default.
- W4317862924 hasConceptScore W4317862924C204787440 @default.
- W4317862924 hasConceptScore W4317862924C27081682 @default.
- W4317862924 hasConceptScore W4317862924C2780210213 @default.
- W4317862924 hasConceptScore W4317862924C2780258809 @default.
- W4317862924 hasConceptScore W4317862924C2781413609 @default.
- W4317862924 hasConceptScore W4317862924C509974204 @default.
- W4317862924 hasConceptScore W4317862924C71924100 @default.
- W4317862924 hasIssue "4_suppl" @default.
- W4317862924 hasLocation W43178629241 @default.
- W4317862924 hasOpenAccess W4317862924 @default.
- W4317862924 hasPrimaryLocation W43178629241 @default.
- W4317862924 hasRelatedWork W1965851372 @default.
- W4317862924 hasRelatedWork W2094153719 @default.
- W4317862924 hasRelatedWork W2115579238 @default.
- W4317862924 hasRelatedWork W2126322332 @default.
- W4317862924 hasRelatedWork W2596055884 @default.
- W4317862924 hasRelatedWork W2885862304 @default.
- W4317862924 hasRelatedWork W3031244932 @default.
- W4317862924 hasRelatedWork W3031675857 @default.
- W4317862924 hasRelatedWork W4205828341 @default.
- W4317862924 hasRelatedWork W4281720666 @default.
- W4317862924 hasVolume "41" @default.
- W4317862924 isParatext "false" @default.
- W4317862924 isRetracted "false" @default.
- W4317862924 workType "article" @default.